ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "RANK/RANKL pathway"

  • Abstract Number: 1997 • 2012 ACR/ARHP Annual Meeting

    Safety and Efficacy of Denosumab Vs Ibandronate in Postmenopausal Women Sub-Optimally Treated with Daily or Weekly Bisphosphonates: A Randomized, Open-Label Study

    Michael A. Bolognese1, Edward Czerwinski2, Henry G. Bone3, Sydney Bonnick4, Neil Binkley5, Alfred Moffett Jr.6, Suresh Siddhanti7, Irene Ferreira8, Prayashi Ghelani9, Rachel Wagman7, Jesse W. Hall7 and Chris Recknor10, 1Bethesda Health Research Center, Bethesda, MD, 2Krakow Medical Center, Krakow, Poland, 3Michigan Bone and Mineral Clinic, Detroit, MI, 4Clinical Research Center of North Texas, Denton, TX, 5University of Wisconsin, Madison, WI, 6OB-GYN Associates of Mid Florida, PA, Leesburg, FL, 7Amgen Inc., Thousand Oaks, CA, 8Amgen Inc., Cambridge, United Kingdom, 9Ovatech Solutions, London, United Kingdom, 10United Osteoporosis Centers, Gainesville, GA

    Background/Purpose: Denosumab, a fully human monoclonal antibody that specifically targets RANKL to inhibit osteoclast formation, function, and survival, reduces risk for vertebral, non-vertebral, and hip…
  • Abstract Number: 1962 • 2012 ACR/ARHP Annual Meeting

    The Specific Role of Glutaredoxin2 Isoform b (Glrx2b) in RANKL-Induced Osteoclastogenesis Through Activation of the p38-MAPK Signaling Pathway

    Chang-Hoon Lee1, Wan-Hee Yoo2, Jin-Jung Choi3, Myong-Joo Hong4, Ji-Min Kim5 and Jeong-Tae Yeon6, 1Department of Internal Medicine, School of medicine, Wonkwang university, Iksan, Chonbuk, South Korea, 2Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, 3Internal Medicine, CHA University Hospital, Seongnam, South Korea, 4Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, 5Division of Rheumatology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea, 6Department of anatomy, school of medicine, Wonkwang university, Iksan, Chonbuk, South Korea

    Background/Purpose: Recently, reactive oxygen species (ROS) and antioxidant enzymes were shown to be closely associated with RANKL-mediated osteoclast differentiation. Although glutaredoxin2 (Glrx2) plays a role…
  • Abstract Number: 1968 • 2012 ACR/ARHP Annual Meeting

    The Specific Role of Vesicle-Associated Membrane Protein-Associated Protein B/C(VapB) As a Regulator of Osteoclastogenesis Via Modulation of Phospholipase Cã(PLCã2-Ca2+-NFAT Signaling

    Chang-Hoon Lee1, Wan-Hee Yoo2, Jin-Jung Choi3, Myong-Joo Hong4, Ji-Min Kim5 and Sik-Won Choi6, 1Department of Internal Medicine, School of Medicine, Wonkwang University, Iksan, Chonbuk, South Korea, 2Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, 3Internal Medicine, CHA University Hospital, Seongnam, South Korea, 4Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, 5Division of Rheumatology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea, 6Department of Anatomy and Institute for Skeletal Disease, School of medicine, Wonkwang university, Iksan, Chonbuk, South Korea

    Background/Purpose: Recently,  Vesicle-Associated Membrane Protein-Associated Protein B/C(VapB) has been shown to regulate calcium homeostasis in myotrophic lateral sclerosis. Calcium signalingis also important in metabolic bone diseases,…
  • Abstract Number: 1977 • 2012 ACR/ARHP Annual Meeting

    Relationship Between Baseline Bone Turnover Marker Levels and Bone Mineral Density Changes in Men with Low Bone Mineral Density Receiving Denosumab or Placebo

    Eric Orwoll1, Ugis Gruntmanis2, Steven Boonen3, Yu-Ching Yang4, Rachel B. Wagman4, Jesse W. Hall4 and Paul D. Miller5, 1Oregon Health and Science University, Portland, OR, 2Dallas Veterans Affairs Medical Center and University of Texas Southwestern Medical Center, Dallas, TX, 3Leuven University, Leuven, Belgium, 4Amgen Inc., Thousand Oaks, CA, 5Colorado Center for Bone Research, Lakewood, CO

    Background/Purpose: Denosumab, a fully human monoclonal antibody to RANKL, has been shown to increase bone mineral density (BMD) in postmenopausal women with high or low…
  • Abstract Number: 1281 • 2012 ACR/ARHP Annual Meeting

    IL-6 Signaling Inhibition Improves Abnormal Bone Homeostasis in Active Rheumatoid Arthritis

    Masayasu Kitano1, Sachie Kitano1, Chieri Sato1, Kazuyuki Fujita1, Takahiro Yoshikawa1, Yuki Katashima1, Masahiro Sekiguchi1, Naoto Azuma1, Naoaki Hashimoto, Shinichiro Tsunoda1, Kiyoshi Matsui1 and Hajime Sano1, 1Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya-city, Japan

    Background/Purpose: Tocilizumab (TCZ) is a humanized monoclonal anti-IL-6 receptor antibody. TCZ has demonstrated efficacy in moderate to severe active rheumatoid arthritis (RA) with inadequate clinical…
  • Abstract Number: 1207 • 2012 ACR/ARHP Annual Meeting

    Impact of Anti Tumor Necrosis Factor-Alpha Therapy in Rheumatoid Arthritis On Osteoclast Activation and B Cells

    Ezinma Ezealah1, Jennifer Hossler1, Jamie Biear1, Christopher A. Cistrone1, Teresa Owen1, Nida Meednu1, Kelly Callahan1, Arumugam Palanichamy1, Ignacio Sanz2, Allen P. Anandarajah1, Ralf G. Thiele1, Darren Tabechian3, R. John Looney1 and Jennifer H. Anolik1, 1Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, 2Rheumatology, Emory University, Atlanta, GA, 3Allergy/Immun/Rheumatology, Univ of Rochester Schl of Med, Rochester, NY

    Background/Purpose:  Serum receptor activator of NFkB ligand (RANKL) and its natural decoy receptor, osteoprotegerin (OPG), play key roles in osteoclast activation. In a group of…
  • Abstract Number: 726 • 2012 ACR/ARHP Annual Meeting

    Dynamic in Vivo Imaging of Th17-Mediated Osteoclastic Bone Resorption in Live Bones by Using Intravital Multiphoton Microscopy

    Junichi Kikuta and Masaru Ishii, Laboratory of Cellular Dynamics, Immunology Frontier Research Center, Osaka University, Osaka, Japan

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint synovial inflammation and progressive cartilage/bone destruction. Although various kinds of cell types, such…
  • Abstract Number: 45 • 2012 ACR/ARHP Annual Meeting

    The Effects of Apremilast On Osteoclasts, Osteoblasts, and Osteocytes

    Mary Adams and Peter Schafer, Department of Translational Development, Celgene Corporation, Summit, NJ

    Background/Purpose: Apremilast (APR), a small molecule specific inhibitor of phosphodiesterase 4, works intracellularly to modulate pro- and anti-inflammatory mediator production in both immune and non-immune…
  • Abstract Number: 2666 • 2012 ACR/ARHP Annual Meeting

    A Link Between B Cells and Bone Erosion in RA: RANKL Production by Memory B Cells

    Nida Meednu1, Teresa Owen2, Hengwei Zhang3, Christopher A. Cistrone1, Lianping Xing4 and Jennifer H. Anolik5, 1Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, 2Allergy, Immununolgy and Rheumatology,, University of Rochester, Rochester, NY, 3Pathology and Laboratory Medicine, University of Rochester, Rochester, NY, 4Pathology & Lab Medicine, University of Rochester, Rochester, NY, 5Medicine- Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disorder that often leads to joint damage. Several lines of evidence suggests the role of B cells…
  • « Previous Page
  • 1
  • 2
  • 3
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology